Smith Barney Cuts King to 'Underperform'

Analyst Angela Larson says drug maker's risk profile has risen markedly due to both FTC and SEC investigations

Smith Barney cut King Pharmaceuticals (KG ) to underperform from in-line.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.